Print
Email
Print Edition StoriesMonday, July 7, 2008
Clarus adds to Pearl’s Series A luster
By Mass High Tech Staff
Cambridge-based venture capital firm Clarus Venures has invested in $18 million dollar financing of Pearl Therapeutics Inc., a California-based biopharmaceutical company developing products for major respiratory diseases.
According to Pearl officials, the new funding is an extension of its Series A round of venture financing, which closed in May 2007. In addition to Clarus, 5AM Ventures of Waltham and California, New Leaf Ventures of New York and California biopharmaceutical firm Nektar Therapeutics participated in the financing.
Pearl, founded in 2006, has raised $36.4 million of venture and other funding to date, according to officials.
Nektar Therapeutics has licensed advanced particle technology to Pearl, and the company it is using to develop technology that will give patients and their health care providers a choice of formulations and dosage strengths of respiratory treatments.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
